Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

1. mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation.Human vaccines & immunotherapeutics · 2025
   Review
2. Aptamers as an approach to targeted cancer therapy.Cancer cell international · 2024
   Review
3. Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer.Molecular cancer · 2023
   Review
4. Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors.Frontiers in bioengineering and biotechnology · 2023
   Review
5. Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy.Frontiers in cell and developmental biology · 2022
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as